Literature DB >> 18842984

Adjuvant mitotane for adrenocortical cancer--a recurring controversy.

Hui Huang1, Tito Fojo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18842984      PMCID： PMC2579650          DOI： 10.1210/jc.2008-0579

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  9 in total

1.  Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.

Authors:  E Baudin; G Pellegriti; M Bonnay; A Penfornis; A Laplanche; G Vassal; M Schlumberger
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

2.  Adjuvant mitotane in adrenocortical carcinoma.

Authors:  Jérôme Bertherat; Joël Coste; Xavier Bertagna
Journal:  N Engl J Med       Date:  2007-09-20       Impact factor: 91.245

3.  Mitotane use in inoperable adrenal cortical carcinoma.

Authors:  J A Lubitz; L Freeman; R Okun
Journal:  JAMA       Date:  1973-03-05       Impact factor: 56.272

4.  Complexing of DDT and o,p'DDD with adrenal cytochrome P-450 hydroxylating systems.

Authors:  R B Young; M J Bryson; M L Sweat; J C Street
Journal:  J Steroid Biochem       Date:  1973-11       Impact factor: 4.292

5.  The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring.

Authors:  H van Slooten; A J Moolenaar; A P van Seters; D Smeenk
Journal:  Eur J Cancer Clin Oncol       Date:  1984-01

6.  Adrenal cortical carcinoma. Clinical features of 138 patients.

Authors:  A M Hutter; D E Kayhoe
Journal:  Am J Med       Date:  1966-10       Impact factor: 4.965

7.  Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.

Authors:  M Terzolo; A Pia; A Berruti; G Osella; A Alì; V Carbone; E Testa; L Dogliotti; A Angeli
Journal:  J Clin Endocrinol Metab       Date:  2000-06       Impact factor: 5.958

8.  Adjuvant mitotane treatment for adrenocortical carcinoma.

Authors:  Massimo Terzolo; Alberto Angeli; Martin Fassnacht; Fulvia Daffara; Libuse Tauchmanova; Pier Antonio Conton; Ruth Rossetto; Lisa Buci; Paola Sperone; Erika Grossrubatscher; Giuseppe Reimondo; Enrico Bollito; Mauro Papotti; Wolfgang Saeger; Stefanie Hahner; Ann-Cathrin Koschker; Emanuela Arvat; Bruno Ambrosi; Paola Loli; Gaetano Lombardi; Massimo Mannelli; Paolo Bruzzi; Franco Mantero; Bruno Allolio; Luigi Dogliotti; Alfredo Berruti
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

9.  o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.

Authors:  T F Hogan; D L Citrin; B M Johnson; S Nakamura; T E Davis; E C Borden
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860
  9 in total
  14 in total

Review 1.  Management of adjuvant mitotane therapy following resection of adrenal cancer.

Authors:  M Terzolo; A Ardito; B Zaggia; F Laino; A Germano; S De Francia; F Daffara; A Berruti
Journal:  Endocrine       Date:  2012-06-17       Impact factor: 3.633

2.  Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells.

Authors:  Insoo Suh; Julie Weng; Gustavo Fernandez-Ranvier; Wen T Shen; Quan-Yang Duh; Orlo H Clark; Electron Kebebew
Journal:  Arch Surg       Date:  2010-03

3.  Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.

Authors:  Matthias Kroiss; Silviu Sbiera; Sabine Kendl; Max Kurlbaum; Martin Fassnacht
Journal:  Horm Cancer       Date:  2016-09-08       Impact factor: 3.869

Review 4.  Management of adrenal cancer: a 2013 update.

Authors:  M Terzolo; F Daffara; A Ardito; B Zaggia; V Basile; L Ferrari; A Berruti
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

5.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

6.  Gaining traction in the treatment of adrenocortical carcinoma.

Authors:  Lawrence S Kirschner
Journal:  J Clin Endocrinol Metab       Date:  2013-01       Impact factor: 5.958

7.  Progress in Endocrine Neoplasia.

Authors:  Samuel A Wells
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

Review 8.  Adrenocortical carcinoma: a clinician's update.

Authors:  Martin Fassnacht; Rossella Libé; Matthias Kroiss; Bruno Allolio
Journal:  Nat Rev Endocrinol       Date:  2011-03-08       Impact factor: 43.330

9.  A G-CSF-secreting adrenal carcinoma with rhabdoid-like differentiation causing leukocytosis.

Authors:  Emil Lou; Jeremy Goodwin; David N Howell; John Hicks; L Brett Caram
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

10.  Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma.

Authors:  Tobias Else; Andrew R Williams; Aaron Sabolch; Shruti Jolly; Barbra S Miller; Gary D Hammer
Journal:  J Clin Endocrinol Metab       Date:  2013-12-03       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.